Dual-Tracer Theranostic PET

NACompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

December 8, 2022

Primary Completion Date

June 4, 2024

Study Completion Date

June 4, 2024

Conditions
Neuroendocrine TumorsProstate Cancer
Interventions
DIAGNOSTIC_TEST

Single-Tracer FDG PET/CT Exam

"The PET technologist will administer approximately 15 millicuries (mCi) of FDG intravenously, and the participant will remain resting during the tracer uptake period. A CT topogram will be obtained, and the PET imaging field-of-view (FOV) selected. The PET scan will then be acquired, acquiring 5 back-to-back whole-body (eyes-to-thighs, or similar) scans, providing 5 sequential PET images."

DIAGNOSTIC_TEST

Single-Tracer Cu64-DOTATATE PET/CT Exam

"The PET technologist will administer with approximately 4 mCi Cu64-DOTATATE intravenously, and the participant will remain resting during the tracer uptake period. A CT topogram will be obtained, and the PET imaging field-of-view (FOV) selected. The PET scan will then be acquired, acquiring 5 back-to-back whole-body (eyes-to-thighs, or similar) scans, providing 5 sequential PET images."

DIAGNOSTIC_TEST

Single-Tracer Ga68-DOTATATE PET/CT Exam

"The PET technologist will administer with with approximately 5 mCi Ga68-DOTATATE intravenously, and the participant will remain resting during the tracer uptake period. A CT topogram will be obtained, and the PET imaging field-of-view (FOV) selected. The PET scan will then be acquired, acquiring 5 back-to-back whole-body (eyes-to-thighs, or similar) scans, providing 5 sequential PET images."

DIAGNOSTIC_TEST

Single-Tracer PSMA PET/CT Exam

"The PET technologist will administer with with approximately 7 mCi Ga68-PSMA-11 intravenously, and the participant will remain resting during the tracer uptake period. A CT topogram will be obtained, and the PET imaging field-of-view (FOV) selected. The PET scan will then be acquired, acquiring 5 back-to-back whole-body (eyes-to-thighs, or similar) scans, providing 5 sequential PET images."

Trial Locations (1)

84112

Huntsman Cancer Institute, Salt Lake City

All Listed Sponsors
collaborator

MultiFunctional Imaging LLC

UNKNOWN

collaborator

National Cancer Institute (NCI)

NIH

lead

University of Utah

OTHER